Novo Nordisk announced that the Food and Drug Administration (FDA) has approved a new 30mg/3.0mL strength of Norditropin (somatropin [rDNA origin] injection) FlexPro pen.
Norditropin FlexPro is indicated for growth failure in children due to inadequate endogenous GH secretion, children with short stature associated with Noonan or Turner syndrome, children with short stature born small for gestational age (SGA) with no catch-up growth by age 2–4 years, and for adults with childhood-onset or adult-onset GH deficiency.
Somatotropin binds to a dimeric growth hormone receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects.
Norditropin FlexPro Pen is already available in 5mg/1.5mL, 10mg/1.5mL, and 15mg/1.5mL strengths. The new 30mg/3.0mL prefilled pen is expected to be available by April 2015.
more information call (888) 668-6444 or visit Norditropin.com.